REDDROP LAUNCHES PERIOD SWIMWEAR FOR TEENS AND TWEENS
ATLANTA, May 23, 2025 /PRNewswire/ — RedDrop, a rising star in the wellness industry for its innovative tween period care and education, today drops its newest product to accompany girls in all their summertime activities: period swimwear. Launching just in time for the summer season and May's Menstrual Awareness Month, RedDrop period swimwear will be available for sale on May 23, 2025 at TryRedDrop.com.
RedDrop's period swimwear can be worn any day during a girl's period as an alternative to pads or tampons. It's designed for versatility as a bikini bottom in classic black that can mix and match with any bikini top. As with RedDrop's other menstrual products, the bikini bottoms are specifically made for girls' smaller, changing bodies. The age-appropriate swimwear comes in a range of sizes from Youth XS (Kids size 8-10) to Women's XL (Juniors size 14-16).
'We designed our period swimwear to be a perfect fit for tweens to participate in summer activities uninterrupted, from a day at the pool or beach to a weekend at the lake to sleepaway camp,' said Dana Roberts, Co-Founder of RedDrop. 'The swimwear also comes with empowering, straightforward educational resources to build confidence and body literacy. All girls should have access to affordable period care products made to meet their needs, no matter when their period starts.'
RedDrop's period swimwear is made from fragrance-free, PFAS-free and non-toxic materials that form moisture-wicking layers and flexible fits that move with growing – and swimming – bodies. The bottoms hold up to two light pads or three light tampons of flow (up to 12-18 grams) and won't get waterlogged after a dip in the pool.
The new product launch comes on the heels of significant investments in RedDrop and its mission to address menstrual inequity with tween period products and educational resources. In November 2024, the minority- and women-owned company won the $1 million grand prize from Black Ambition, Pharrell Williams' non-profit organization to support Black and Hispanic Entrepreneurs. In February 2025, RedDrop won the Fifteen Percent Pledge Achievement Award totaling $200K. The Fifteen Percent Pledge is a racial equity and economic justice non-profit that addresses inequities in the American consumer economy and works towards closing the racial wealth gap.
To connect and learn more about RedDrop, please visit www.tryreddrop.com. Follow us on Instagram (@reddrop), Facebook (@reddropco), YouTube (@tryreddrop) and TikTok (@reddropco) to stay up to date with us.
About RedDropRedDrop is a wellness brand committed to creating inclusive and innovative period products for tween girls to feel their best during their new stage of life. With a focus on properly sized period products and education-backed solutions, RedDrop is on a mission to normalize periods and period preparation for tweens, teens and their families. Since 2019, RedDrop has made period care more accessible for over 1 million teens and tweens.
Media Contact: Mallory Smith, mallory@dittoepr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
9 hours ago
- The Star
Redesigning the speculum for women's comfort
Lilium, a 3D-printed plastic alternative to the gynaecological speculum (bottom), and a traditional metal speculum (top). — Photos: AFP It is cold, hard, metallic and commonly associated with pain. No, it is not a medieval torture instrument, but the vaginal speculum, which is used every day around the world for essential gynaecological examinations. Two engineers at Delft University in the Netherlands are now rethinking the decades-old design of the speculum, long dreaded by many patients, to make it less intimidating and less painful. 'I have a lot of experience with the vaginal speculum unfortunately,' engineer Tamara Hoveling said. 'I've never seen it as a pleasurable experience and I've always wondered why it looks like this.' The PhD candidate in medical industrial design then delved into the dark history behind the creation of the speculum – one version of which was developed by American doctor James Marion Sims 180 years ago. It was 'tested on enslaved women without permission', said the 29-year-old. 'So that motivated me even more to take on this project.' Hoveling teamed up with Ariadna Izcara Gual, who was then working on her master's in industrial design engineering at Delft. 'As I was doing a lot of interviews, I was doing those sort of sketches with the same sort of shape, but people were still scared of the device,' said the 28-year-old Spanish researcher. The Cusco speculum – the most commonly-used model – is a metal device with a handle, beak and screw to adjust how wide it opens once inside the vagina. For many, its insertion is uncomfortable or even painful, and causes anxiety. 'When you get scared, your muscles clamp together and that makes it even harder to relax. 'Then the speculum is opened, pushing against these tense muscles and making it even more painful,' Hoveling said. 'So I tried to look for shapes that might be related to the reproductive organs, like, for example, the flower, that also opens.' The result was a prototype called the Lilium, named after the lily flower. Hoveling shows 3D-printed prototypes of Lilium. On the table are also metal speculums, which are the current standard equipment used for vaginal examinations. Like the more familiar tampon, it is made of soft plastic and has an applicator. 'It's designed with the patient in mind, rather than the doctor. 'And we're really trying to improve the comfort aspect in a sensitive spot.' The Lilium also meets doctors' needs. Its three-sided opening keeps the vaginal walls from collapsing, allowing better visibility during examinations. The Lilium remains at an early stage, with further ergonomic testing and material research needed to refine the prototype. The researchers must still secure safety certifications, run human trials and obtain regulatory approval before it can reach clinics. To fund the next phase, they launched a crowdfunding campaign that quickly drew media attention in the Netherlands. Within just two days, the campaign raised 100,000 euros (RM493,270), far surpassing expectations. 'It's also a sign. It's proof there are people who really want change, that there is a real problem here, and that the current market solutions are not the best,' Hoveling said. 'I've received a lot of emails from women who told me they actually don't go to the gynaecologist because of this device, because they're scared, because they have a traumatic experience.' Cervical cancer is the fourth most common cancer among women, according to the World Health Organization (WHO). It can be detected via a smear test or HPV (human papillomavirus) screening – both performed using a speculum. With funding to allow this new gynaecological tool to be developed properly, the Lilium could be saving lives within five years. – By Stéphanie Hamel/AFP
Malaysian Reserve
15 hours ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
Malaysian Reserve
a day ago
- Malaysian Reserve
NAMI Statement on Executive Order Targeting Homelessness and Criminalizing Mental Illness
ARLINGTON, Va., July 25, 2025 /PRNewswire/ — Yesterday, the White House released a new Executive Order, 'Ending Crime and Disorder on America's Streets,' which directs federal agencies to make it easier to involuntarily treat people with serious mental illnesses as part of a bid to address homelessness across the United States. While addressing the nationwide homelessness crisis is urgent and necessary, yesterday's executive order promoting institutionalization of people with mental illness raises grave concerns for NAMI and our community. NAMI's Chief Executive Officer Daniel H. Gillison, Jr. said: 'Mental illness is not a crime, and people with mental illness deserve to be treated as human beings, with dignity and respect. While we agree that homelessness is an urgent crisis in our country, to truly address the systemic causes of this crisis, we should be pouring resources into treatment to improve early access to care and investing in supportive housing and other wrap-around services. It's always ideal – and best – for an individual to engage in their own treatment. Yet, too many NAMI families know that isn't always possible. Unfortunately, yesterday's order concerningly focuses broadly on institutionalization and not on real solutions that we know work in helping people lead better lives.' NAMI believes that in the rare instances where voluntary engagement in treatment is not possible, involuntary commitment should be used only as a last resort and only when it is believed to be in the best interests of the individual. While it is unclear how the executive order will be carried out since state law governs the process of involuntary civil commitment, the order also urges moving away from a 'housing first' approach, which has been successful in helping individuals stay connected to treatment and reduce homelessness. While NAMI is troubled by the overall order, it does include a direction to federal agencies to support crisis response services and prioritize funding for mental health and drug courts – strategies that NAMI supports. This executive order comes at a time when significant cuts are being made to mental health services nationwide. Earlier this month, Congress passed legislation that will drastically cut Medicaid and Supplemental Nutrition Assistance Program (SNAP) benefits, impacting millions of Americans. The Administration has rescinded more than $1 billion in grants from the Substance Abuse and Mental Health Services Administration (SAMHSA), with more cuts proposed for the next fiscal year. These changes will result in far too many people being unable to get the treatment they need. When that happens, more people will be arrested, incarcerated, land in emergency rooms, lose their connection to family and community, and ultimately become homeless. NAMI's Chief Advocacy Officer Hannah Wesolowski said: 'Rather than providing access to critical mental health services, this executive order appears to prioritize coercive tactics to move people who are homeless out of the public eye. This does nothing to address the root causes of homelessness, runs a high risk of exacerbating the homelessness crisis, and is not the way to address our mental health needs. People with mental illness deserve better.' For more information on the public policies that NAMI supports, visit
